Tocopherols in the prevention and treatment of atherosclerosis and related cardiovascular disease

Clinical Cardiology

Volumn 38, Issue 9, 2015, Pages 570-576

  Mathur, Pankaj ^a   Ding, Zufeng ^a   Saldeen, Tom ^a   Mehta, Jawahar L ^a  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BETA TOCOPHEROL; DELTA TOCOPHEROL; GAMMA TOCOPHEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; TOCOPHEROL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DRUG POTENCY; DRUG STRUCTURE; HEART INFARCTION; HEART PROTECTION; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; LIPID DEGRADATION; LIPID OXIDATION; LIPID TRANSPORT; NITROSATIVE STRESS; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS; ANIMAL; ARTERY; ATHEROSCLEROTIC PLAQUE; DRUG EFFECTS; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; ARTERIES; ATHEROSCLEROSIS; HUMANS; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; TOCOPHEROLS; TREATMENT OUTCOME;

EID: 84942836732     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22422     Document Type: Review

References (75)

1. Duff GL, McMillan GC,. Pathology of atherosclerosis. Am J Med. 1951; 11: 92-108.
2. Gofman JW, Jones HB, Lindgren FT, et al., Blood lipids and human atherosclerosis. Circulation. 1950; 2: 161-178.
3. Gofman JW, Lindgren FT, Elliot H,. Ultracentrifugal studies of lipoproteins of human serum. J Biol Chem. 1949; 179: 973-979.
4. Steinberg D., Research related to underlying mechanisms in atherosclerosis. Circulation. 1979; 60: 1559-1565.
5. Henriksen T, Mahoney EM, Steinberg D,. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A. 1981; 78: 6499-6503.
6. Parthasarathy S, Quinn MT, Steinberg D,. Is oxidized low density lipoprotein involved in the recruitment and retention of monocyte/macrophages in the artery wall during the initiation of atherosclerosis? Basic Life Sci. 1988; 49: 375-380.
7. Ross R., Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340: 115-126.
8. Ross R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801-809.
9. Kummerow FA, Olinescu RM, Fleischer L, et al., The relationship of oxidized lipids to coronary artery stenosis. Atherosclerosis. 2000; 149: 181-190.
10. Mehta JL,. Oxidized or native low-density lipoprotein cholesterol: which is more important in atherogenesis? J Am Coll Cardiol. 2006; 48: 980-982.
11. Mehta JL, Saldeen TG, Rand K,. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol. 1998; 31: 1217-1225.
12. Brown MS, Goldstein JL,. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983; 52: 223-261.
13. Moore KJ, Freeman MW,. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol. 2006; 26: 1702-1711.
14. Pant S, Deshmukh A, Gurumurthy GS, et al., Inflammation and atherosclerosis-revisited. J Cardiovasc Pharmacol Ther. 2014; 19: 170-178.
15. Victor VM, Rocha M, Solá E, et al., Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des. 2009; 15: 2988-3002.
16. Hink U, Li H, Mollnau H, et al., Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001; 88: E14-E22.
17. Landmesser U, Harrison DG,. Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation. 2001; 104: 2638-2640.
18. Ding Z, Liu S, Wang X, et al., LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis. Cardiovasc Res. 2014; 103: 619-628.
19. Sugamura K, Keaney JF Jr., Reactive oxygen species in cardiovascular disease. Free Radic Biol Med. 2011; 51: 978-992.
20. Furchgott RF, Zawadzki JV,. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288: 373-376.
21. Anderson TJ,. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol. 1999; 34: 631-638.
22. Alderton WK, Cooper CE, Knowles RG,. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001; 357 (part 3): 593-615.
23. Gutstein DE, Fuster V,. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res. 1999; 41: 323-333.
24. Esper RJ, Nordaby RA, Vilariño JO, et al., Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol. 2006; 5: 4.
25. Wennmalm A., Endothelial nitric oxide and cardiovascular disease. J Intern Med. 1994; 235: 317-327.
26. Bretõn-Romero R, Acín-Perez R, Rodríguez-Pascual F, et al., Laminar shear stress regulates mitochondrial dynamics, bioenergetics responses and PRX3 activation in endothelial cells. Biochim Biophys Acta. 2014; 1843: 2403-2413.
27. McCarty MF,. Gamma-tocopherol may promote effective NO synthase function by protecting tetrahydrobiopterin from peroxynitrite. Med Hypotheses. 2007; 69: 1367-1370.
28. Stroes E, Kastelein J, Erkelens W, et al., Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997; 99: 41-46.
29. Jiang Q., Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic Biol Med. 2014; 72: 76-90.
30. Sokol RJ,. Vitamin E and neurologic deficits. Adv Pediatr. 1990; 37: 119-148.
31. Christen S, Woodall AA, Shigenaga MK, et al., Gamma-tocopherol traps mutagenic electrophiles such as NO(x) and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci U S A. 1997; 94: 3217-3222.
32. Cooney RV, Franke AA, Harwood PJ, et al., Gamma-tocopherol detoxification of nitrogen dioxide: superiority to alpha-tocopherol. Proc Natl Acad Sci U S A. 1993; 90: 1771-1775.
33. Kaul N, Devaraj S, Jialal I,. Alpha-tocopherol and atherosclerosis. Exp Biol Med (Maywood). 2001; 226: 5-12.
34. Devaraj S, Jialal I,. The effects of alpha-tocopherol on crucial cells in atherogenesis. Curr Opin Lipidol. 1998; 9: 11-15.
35. Ricciarelli R, Tasinato A, Clément S, et al., Alpha-tocopherol specifically inactivates cellular protein kinase C alpha by changing its phosphorylation state. Biochem J. 1998; 334 (part 1): 243-249.
36. Keaney JF Jr, Simon DI, Freedman JE,. Vitamin E and vascular homeostasis: implications for atherosclerosis. FASEB J. 1999; 13: 965-975.
37. Heitzer T, Ylä Herttuala S, Wild E, et al., Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J Am Coll Cardiol. 1999; 33: 499-505.
38. Boscoboinik D, Szewczyk A, Hensey C, et al., Inhibition of cell proliferation by alpha-tocopherol: role of protein kinase C. J Biol Chem. 1991; 266: 6188-6194.
39. Reaven PD, Khouw A, Beltz WF, et al., Effect of dietary antioxidant combinations in humans: protection of LDL by vitamin E but not beta-carotene. Arterioscler Thromb. 1993; 13: 590-600.
40. O'Keefe JH Jr, Lavie CJ Jr, McCallister BD,. Insights into the pathogenesis and prevention of coronary artery disease. Mayo Clin Proc. 1995; 70: 69-79.
41. Hennig B, Boissonneault GA, Wang Y,. Protective effects of vitamin E in age-related endothelial cell injury. Int J Vitam Nutr Res. 1989; 59: 273-279.
42. Wallert M, Schmölz L, Galli F, et al., Regulatory metabolites of vitamin E and their putative relevance for atherogenesis. Redox Biol. 2014; 2: 495-503.
43. Stephens NG, Parsons A, Schofield PM, et al., Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996; 347: 781-786.
44. Boaz M, Smetana S, Weinstein T, et al., Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000; 356: 1213-1218.
45. Salonen RM, Nyyssönen K, Kaikkonen J, et al., Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: ASAP study. Circulation. 2003; 107: 947-953.
46. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial [published corrections appear in Lancet. 2001;357:642 and Lancet. 2007;369:106]. Lancet. 1999;354:447-455.
47. Rapola JM, Virtamo J, Ripatti S, et al., Effects of alpha-tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris. Heart. 1998; 79: 454-458.
48. Rapola JM, Virtamo J, Ripatti S, et al., Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997; 349: 1715-1720.
49. Yusuf S, Dagenais G, Pogue J, et al,; Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 154-160.
50. Vivekananthan DP, Penn MS, Sapp SK, et al., Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials [published correction appears in Lancet. 2004;363:662]. Lancet. 2003; 361: 2017-2023.
51. Jiang Q, Lykkesfeldt J, Shigenaga MK, et al., Gamma-tocopherol supplementation inhibits protein nitration and ascorbate oxidation in rats with inflammation. Free Radic Biol Med. 2002; 33: 1534-1542.
52. Jiang Q, Ames BN,. Gamma-tocopherol, but not alpha-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J. 2003; 17: 816-822.
53. Jiang Q, Elson-Schwab I, Courtemanche C, et al., Gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A. 2000; 97: 11494-11499.
54. Himmelfarb J, Kane J, McMonagle E, et al., Alpha and gamma-tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int. 2003; 64: 978-991.
55. Handelman GJ, Machlin LJ, Fitch K, et al., Oral alpha-tocopherol supplements decrease plasma gamma-tocopherol levels in humans. J Nutr. 1985; 115: 807-813.
56. Baker H, Handelman GJ, Short S, et al., Comparison of plasma alpha and gamma-tocopherol levels following chronic oral administration of either all-rac-alpha-tocopheryl acetate or RRR-alpha-tocopheryl acetate in normal adult male subjects. Am J Clin Nutr. 1986; 43: 382-387.
57. Freedman JE, Farhat JH, Loscalzo J, et al., Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation. 1996; 94: 2434-2440.
58. Saldeen T, Li D, Mehta JL,. Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis [published correction appears in J Am Coll Cardiol. 2000;35:263]. J Am Coll Cardiol. 1999; 34: 1208-1215.
59. Conti CR, Mehta JL,. Acute myocardial ischemia: role of atherosclerosis, thrombosis, platelet activation, coronary vasospasm, and altered arachidonic acid metabolism. Circulation. 1987; 75 (6 part 2): V84-V95.
60. Fuster V, Badimon L, Badimon JJ, et al., The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992; 23; 326: 242-250.
61. Liu M, Wallmon A, Olsson-Mortlock C, et al., Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms. Am J Clin Nutr. 2003; 77: 700-706.
62. Liu M, Wallin R, Wallmon A, et al., Mixed tocopherols have a stronger inhibitory effect on lipid peroxidation than alpha-tocopherol alone. J Cardiovasc Pharmacol. 2002; 39: 714-721.
63. Liu M, Wallin R, Saldeen T,. Effect of mixed tocopherols on eNOS, SOD and PKC in leukocytes in human subjects. Nutr Res. 2002; 22: 1253-1263.
64. Ohrvall M, Sundlöf G, Vessby B,. Gamma, but not alpha, tocopherol levels in serum are reduced in coronary disease patients. J Intern Med. 1996; 239: 111-117.
65. Kontush A, Spranger T, Reich A, et al., Lipophilic antioxidants in blood plasma as markers of atherosclerosis: the role of alpha-carotene and gamma tocopherol. Atherosclerosis. 1999; 144: 117-122.
66. Vucinic L, Singh I, Spargo FJ, et al., Gamma-tocopherol supplementation prevents exercise-induced coagulation and platelet aggregation. Thromb Res. 2010; 125: 196-199.
67. Ricciarelli R, Azzi A,. Regulation of recombinant PKC alpha activity by protein phosphatase 1 and protein phosphatase 2A. Arch Biochem Biophys. 1998; 355: 197-200.
68. Ricciarelli R, Zingg JM, Azzi A,. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation. 2000; 102: 82-87.
69. Li D, Saldeen T, Mehta JL,. Gamma-tocopherol decreases ox-LDL-mediated activation of nuclear factor-kappaB and apoptosis in human coronary artery endothelial cells. Biochem Biophys Res Commun. 1999; 259: 157-161.
70. de Nigris F, Franconi F, Maida I, et al., Modulation by alpha- and gamma-tocopherol and oxidized low-density lipoprotein of apoptotic signaling in human coronary smooth muscle cells. Biochem Pharmacol. 2000; 59: 1477-1487.
71. Devaraj S, Leonard S, Traber MG, et al., Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med. 2008; 44: 1203-1208.
72. Mah E, Noh SK, Ballard KD, et al., Supplementation of a γ-tocopherol-rich mixture of tocopherols in healthy men protects against vascular endothelial dysfunction induced by postprandial hyperglycemia. J Nutr Biochem. 2013; 24: 196-203.
73. Bruno RS, Traber MG,. Vitamin E biokinetics, oxidative stress and cigarette smoking. Pathophysiology. 2006; 13: 143-149.
74. Singh I, Turner AH, Sinclair AJ, et al., Effects of gamma-tocopherol supplementation on thrombotic risk factors. Asia Pac J Clin Nutr. 2007; 16: 422-428.
75. Wade L, Nadeem N, Young IS, et al., α-Tocopherol induces proatherogenic changes to HDL2 and HDL3: an in vitro and ex vivo investigation. Atherosclerosis. 2013; 226: 392-397.